New-onset Diabetes and Left Ventricular Hypertrophy in Renal Transplantation

NCT ID: NCT01976689

Last Updated: 2013-11-07

Basic Information

• Recruitment Status: COMPLETED
• Total Enrollment: 159 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2012-03-31
• Study Completion Date: 2013-09-30

Brief Summary

New-onset diabetes (NODAT) after solid organ transplantation is an important clinical challenge associated to increased risk of cardiovascular (CV) events. In end-stage renal disease (ESRD) patients, the impact of arterial stiffness on all-cause and CV mortality has been clearly documented. Arterial stiffness has a pivotal role in the genesis of high blood pressure (SBP), increased left ventricular hypertrophy (LVH), and consequently CV mortality. Both LVH and arterial stiffness are independent determinants of CV disease in patients with ESRD. The aim of this study is to evaluate the relationship between post-transplant new-onset diabetes and arterial stiffness and left ventricular mass index (LVMI) in kidney transplant recipients.

Detailed Description

All patients' data were recorded from clinical charts. Visits in out patient clinic were organized as follows: three visits per week during the first 2 weeks; two visits per week until day 60; weekly visits until day 120; monthly visits during the first year; one visit every other month during the second year; and four visits per year thereafter until death or end-stage renal disease (i.e. dialysis or retransplantation). The following parameters were collected; 1) age, 2) gender, 3) posttransplantation duration, 4) pretransplant hemodialysis duration, 4) acute rejection episodes, 5) use of statins, ace inhibitor (ACE) or angiotensin receptor blocker (ARB), 6) immunosuppressive treatment (mycophenolate, cyclosporine, tacrolimus, and sirolimus use), 7) pretransplant lipid profile (values in the last month before transplantation), 8) posttransplant lipid profile (mean value), 9) FPG and HbA1c levels (mean value), 10) office blood pressure measurements, 11) hemoglobin, calcium, phosphorus, albumine and parathyroid hormone levels, 12) creatinine and estimated GFR (MDRD equation) and, 13) cytomegalovirus (CMV) infection history. Mean values were arithmetic means of each parameter that were collected from patient charts at 3 monthly basis after the first posttransplant 6 months while other parameters (12-16) were collected as single values at study inclusion.

All patients were under 5 mg prednisolone treatment within the immuno suppressive regimen. Maintenance immunosuppressive treatment included prednisone with a gradual tapering and mycophenolate mofetil or sodium associated with cyclosporine, tacrolimus or sirolimus in most patients. Target through levels at 3 months were 150-250 ng/ml for cyclosporine and 8-12 ng/ml for tacrolimus and sirolimus. Anti-diabetic treatment modalities (diet and lifestyle changes, oral anti-diabetic drugs or insulin) were also recorded for patients with NODAT.

Body compositions of all patients were analyzed by using the Body Composition Analyzer (Tanita BC-420MA). Fat mass, fat free mass, muscle mass, visceral fat mass and body mass index were calculated for each patient.

All patients underwent echocardiographic examinations (Siemens Acuson C256, Mountain view, California 2000 with 3V2c transducer probe) by the same operator and left ventricular mass was calculated according to the Devereux formula and indexed to body surface area to give LVMI (g/m2). Left ventricular mass index values greater than 130g/m2 (n: 57) were defined as high left ventricular mass.

Pulse wave velocity (PWv) is defined as the velocity of the arterial pulse for moving along the vessel wall. Pulse wave velocity along the aorta was measured by using two ultrasound or pressure sensitive transducers fixed transcutaneously over the course of a pair of arteries separated by a known distance: the femoral and right common carotid arteries. PWV was calculated from measurements of pulse transit time and the distance, according to the following formula: PWV (m/s)= distance (m)/transit time (s). Measurement of PWV values was con-ducted after abstinence from caffeine or smoking and after an overnight fast without intake of antihypertensive drugs. PWV was determined by using the SphygmoCor CvMs V9 system and values > 7 m/s was defined as increased.

Conditions

Diabetes Mellitus Nos New Onset; Hypertrophy, Left Ventricular; Vascular Stiffness

Keywords

Glucose Regulation; Left Ventricular Hypertrophy; New-onset Diabetes; Renal Transplantation

Study Design

• Observational Model Type: CASE_CONTROL
• Study Time Perspective: RETROSPECTIVE

Study Groups

Patients with New-onset Diabetes

New-onset diabetes after transplantation was defined as a fasting plasma glucose (FPG) level ≥ 126 mg/dL (7 mmol/L) or symptoms of diabetes plus casual plasma glucose concentrations ≥200 mg/dL (11.1 mmol/L), confirmed by repeat testing on a different day. According to these criteria, 63 patients were diagnosed as NODAT between years 2007-2010 but after the exclusion criteria of our study 57 patients with and 102 patients without NODAT were included in the study.

No interventions assigned to this group

Patients without NODAT

New-onset diabetes after transplantation was defined as a fasting plasma glucose (FPG) level ≥ 126 mg/dL (7 mmol/L) or symptoms of diabetes plus casual plasma glucose concentrations ≥200 mg/dL (11.1 mmol/L), confirmed by repeat testing on a different day. According to these criteria, 63 patients were diagnosed as NODAT between years 2007-2010 but after the exclusion criteria of our study 57 patients with and 102 patients without NODAT were included in the study.

No interventions assigned to this group

Eligibility Criteria

Inclusion Criteria

Patients who underwent renal transplantation between years 2007-2010 in our transplantation clinic with routine periodical follow-up.

Exclusion Criteria

• irregular drug usage or patient incompliance
• lack of regular follow-up data
• pretransplant diabetes mellitus history
• bone marrow transplant or other solid organs before or at the time of transplantation (including previous kidney transplantation)
• malign disease, rheumatologic or chronic inflammatory disease of unknown origin, systemic vasculitis history
• acute rejection periods after the first year of transplantation
• unstable cardiac disease including heart failure (ejection fraction < %50) and/or ischemic heart disease history (myocardial infarction, need for cardiac revascularization)
• atrial fibrillation or elevated heart rate (>100 beats/min)
• coronary bypass before or after transplantation
• transiently elevated fasting plasma glucose (FPG) or diabetic blood glucose profile during the first 3 posttransplant months
• graft failure [glomerular filtration (GFR) rate < 30 mL/min]
• history of peritoneal dialysis before transplantation

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Baskent University

OTHER

Sponsor Role: lead

Responsible Party

Mehtap Erkmen Uyar

Md, Neprology Fellow

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Siren Sezer, Prof. Dr.

Role: STUDY_CHAIR

Baskent University, Department of Nephrology

Locations

Baskent University Medical School

Ankara, , Turkey (Türkiye)

Countries

Turkey (Türkiye)

Other Identifiers

TIBU009158

Identifier Type: -

Identifier Source: org_study_id